Singapore, Oct. 19 -- Cell Therapies Pty Ltd (CTPL) and S2N.Bio have commenced technology transfer of S2N's cell therapy candidate for Alzheimer's disease. The transfer will enable GMP manufacture of clinical trial material for S2N's first-in-human study in Australia.

CTPL and S2N are collaborating members of the Solutions for Manufacturing Advanced Regenerative Therapies (SMART) Cooperative Research Centre (CRC) ("SmartCRC"), which is co-funding elements of the project as part of its mission to accelerate the translation of innovative health technologies from research through to clinical and commercial outcomes.

The technology transfer will establish S2N's cell manufacturing process under GMP conditions, establish GMP analytical method...